We found a similar pharmacogenetic interaction result after adjusting for cigarettes per day (CPD; Table S32). We identified the utility of CHRNA5 genotypes in predicting response to cNRT (Fig 1A): the clinical impact of this interaction was exemplified by the number needed to treat (NNT), which varied with genotypes. Smokers with AA and GA genotypes were more likely to respond to cNRT (NNT=2.6 and 3.9, respectively). Conversely, smokers with the GG genotype received less benefit from cNRT (NNT=19.2).
